Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

22 december 2015 uppdaterad av: Boehringer Ingelheim

Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)

The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating.

The currently available medications pegylated interferon alfa and ribavirin for hepatitis C ca have considerable adverse events in patients and in many cases are not sufficiently effective. This is particularly the case in treatment of patients infected with genotype 1 of HCV.

A combination therapy of these new substances without pegylated interferon alfa may be associated with fewer adverse events that currently available (pegylated interferon-alfa-based) medication and may also provide a treatment option to the large number of patients with contraindications or intolerance to pegylated interferon alfa.

This clinical trial (1241.21) currently consists of 3 distinct studies: Part 1, Part 2 and Part 3.

Part 1 (SOUND-C1) is a 2 armed study as described in experimental arms 1 and 2 below (actual enrollment: 56 patients; randomized and treated: 32) Part 2 (SOUND-C2) is a 5 armed study as described in experimental arms 3 to 7 below (actual enrollment: 465; randomized and treated: 362) Part 3 (SOUND-C3) includes 3 arms as described in experimental arms 8 to 10 below (83 patients randomized and treated)

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

488

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Victoria
      • Heidelberg, Victoria, Australien
        • 1241.21.61002 Boehringer Ingelheim Investigational Site
      • Melbourne, Victoria, Australien
        • 1241.21.61001 Boehringer Ingelheim Investigational Site
      • Clichy, Frankrike
        • 1241.21.33005 Boehringer Ingelheim Investigational Site
      • Grenoble cédex 9, Frankrike
        • 1241.21.33007 Boehringer Ingelheim Investigational Site
      • Lyon, Frankrike
        • 1241.21.33003 Boehringer Ingelheim Investigational Site
      • Marseille, Frankrike
        • 1241.21.33001 Boehringer Ingelheim Investigational Site
      • Montpellier, Frankrike
        • 1241.21.33002 Boehringer Ingelheim Investigational Site
      • Paris, Frankrike
        • 1241.21.33004 Boehringer Ingelheim Investigational Site
      • Paris, Frankrike
        • 1241.21.33008 Boehringer Ingelheim Investigational Site
      • Vandoeuvre Cedex, Frankrike
        • 1241.21.33006 Boehringer Ingelheim Investigational Site
    • California
      • La Jolla, California, Förenta staterna
        • 1241.21.0003 Boehringer Ingelheim Investigational Site
      • San Diego, California, Förenta staterna
        • 1241.21.0006 Boehringer Ingelheim Investigational Site
      • San Francisco, California, Förenta staterna
        • 1241.21.0004 Boehringer Ingelheim Investigational Site
    • Florida
      • Palm Harbor, Florida, Förenta staterna
        • 1241.21.0011 Boehringer Ingelheim Investigational Site
    • Indiana
      • Valparaiso, Indiana, Förenta staterna
        • 1241.21.0013 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Springfield, Massachusetts, Förenta staterna
        • 1241.21.0008 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Fayetteville, North Carolina, Förenta staterna
        • 1241.21.0019 Boehringer Ingelheim Investigational Site
    • Texas
      • Arlington, Texas, Förenta staterna
        • 1241.21.0012 Boehringer Ingelheim Investigational Site
      • Austin, Texas, Förenta staterna
        • 1241.21.0005 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, Förenta staterna
        • 1241.21.0007 Boehringer Ingelheim Investigational Site
      • Houston, Texas, Förenta staterna
        • 1241.21.0010 Boehringer Ingelheim Investigational Site
    • Washington
      • Seattle, Washington, Förenta staterna
        • 1241.21.0017 Boehringer Ingelheim Investigational Site
      • Auckland NZ, Nya Zeeland
        • 1241.21.64001 Boehringer Ingelheim Investigational Site
      • Aveiro, Portugal
        • 1241.21.35103 Boehringer Ingelheim Investigational Site
      • Coimbra, Portugal
        • 1241.21.35104 Boehringer Ingelheim Investigational Site
      • Lisboa, Portugal
        • 1241.21.35101 Boehringer Ingelheim Investigational Site
      • Lisboa, Portugal
        • 1241.21.35105 Boehringer Ingelheim Investigational Site
      • Porto, Portugal
        • 1241.21.35102 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1241.21.40001 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1241.21.40002 Boehringer Ingelheim Investigational Site
      • Bucharest, Rumänien
        • 1241.21.40003 Boehringer Ingelheim Investigational Site
      • Basel, Schweiz
        • 1241.21.41003 Boehringer Ingelheim Investigational Site
      • Bern, Schweiz
        • 1241.21.41006 Boehringer Ingelheim Investigational Site
      • St. Gallen, Schweiz
        • 1241.21.41001 Boehringer Ingelheim Investigational Site
      • Zürich, Schweiz
        • 1241.21.41002 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1241.21.34002 Boehringer Ingelheim Investigational Site
      • Barcelona, Spanien
        • 1241.21.34005 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1241.21.34003 Boehringer Ingelheim Investigational Site
      • Madrid, Spanien
        • 1241.21.34004 Boehringer Ingelheim Investigational Site
      • Majadahonda-Madrid, Spanien
        • 1241.21.34001 Boehringer Ingelheim Investigational Site
      • Valencia, Spanien
        • 1241.21.34006 Boehringer Ingelheim Investigational Site
      • Berlin, Tyskland
        • 1241.21.49002 Boehringer Ingelheim Investigational Site
      • Berlin, Tyskland
        • 1241.21.49003 Boehringer Ingelheim Investigational Site
      • Düsseldorf, Tyskland
        • 1241.21.49007 Boehringer Ingelheim Investigational Site
      • Esslingen, Tyskland
        • 1241.21.49005 Boehringer Ingelheim Investigational Site
      • Frankfurt am Main, Tyskland
        • 1241.21.49001 Boehringer Ingelheim Investigational Site
      • Hamburg, Tyskland
        • 1241.21.49006 Boehringer Ingelheim Investigational Site
      • Hannover, Tyskland
        • 1241.21.49009 Boehringer Ingelheim Investigational Site
      • Leipzig, Tyskland
        • 1241.21.49004 Boehringer Ingelheim Investigational Site
      • Mainz, Tyskland
        • 1241.21.49008 Boehringer Ingelheim Investigational Site
      • Linz, Österrike
        • 1241.21.43003 Boehringer Ingelheim Investigational Site
      • Wien, Österrike
        • 1241.21.43001 Boehringer Ingelheim Investigational Site
      • Wien, Österrike
        • 1241.21.43002 Boehringer Ingelheim Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria:

  • Chronic hepatitis C virus (HCV) infection of genotype (GT) 1
  • Parts 1-3:Treatment naive to Interferon -alfa (IFN), Pegylated interferon -alfa (PegIFN), ribavirin (RBV), and any direct acting antiviral agent for chronic hepatitis C
  • Part 4: Treatment experienced with confirmed prior virological failure to an approved dose of PegIFN/RBV (null-response)
  • HCV RNA >=10,000 IU/mL at screening
  • Liver biopsy within two years or fibroscan within six months prior to baseline
  • Liver biopsy within two years or fibroscan within 6 months prior to screening
  • Age 18-75 years

Exclusion criteria:

  • Hepatitis C virus (HCV) infection of mixed genotype
  • Evidence of liver disease due to causes other than chronic HCV infection
  • Positive ELISA for human immunodeficiency virus (HIV)
  • Hepatitis B virus (HBV) infection
  • Decompensated liver disease or history of decompensated liver disease
  • Active or suspected malignancy within the last 5 years
  • Ongoing or historical photosensitivity or recurrent rash
  • History of alcohol or drug abuse (except cannabis) within the past 12 months
  • Body mass index (BMI)I <18 or > 35 kg/m2
  • Usage of any investigational drugs within 30 days prior to enrolment, or 5 half-lives, whichever is longer; o the planned usage of an investigational drug during the course of the current study
  • Known hypersensitivity to any ingredient of the study drugs
  • A condition that is defined as one which in the opinion of the investigator may interfere with the patient's capability for participation in the trial or may influence the results of the trial
  • Alpha fetoprotein >100ng/mL at screening; if >20ng/mL and <=100ng/mL, patients can be included if there is no evidence of liver cancer in an appropriate imaging study within 6 months prior to randomisation
  • Total bilirubin > 2 mg/dL with ratio of direct/indirect > 1
  • AST or ALT >5xULN
  • INR prolonged to >1.7xULN
  • Requirement for chronic systemic corticosteroids
  • Received concomitant systemic antiviral, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to enrolment or 5 half-lives, whichever is longer
  • Received silymarin or glycyrrhizin or Sho-saiko-to within 30 days prior to enrolment
  • Contraindications pertaining to PegIFN or RBV

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: 2
4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 1
4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 3
16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 4
28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 5
40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 6
28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
40 weeks, QD
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
48 weeks, according to label
40 weeks, according to label
28 weeks, QD
16 weeks, QD
24 weeks, according to label
28 weeks, high dose BID
Experimentell: 7
28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 8
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 9
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 10
24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 11
16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID
Experimentell: 12
24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
28 weeks, high dose, TID
40 weeks, QD
4 weeks, low dose TID
24 weeks, QD
16 weeks, according to label
28 weeks, according to label
40 weeks, high dose, TID
24 weeks, very high dose, BID
16 weeks, standard dose, BID
48 weeks, according to label
40 weeks, according to label
16 weeks, high dose, TID
28 weeks, QD
16 weeks, QD
24 weeks, according to label
24 weeks, standard dose, BID
16 weeks, high dose, BID
24 weeks, high dose, TID
4 weeks, high dose, TID

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part 1: Rapid Virological Response (RVR)
Tidsram: 4 weeks
Part 1: Rapid virological response (RVR), defined as Hepatitis C Virus Ribonucleic acid (HCV RNA) <25IU/mL at Week 4 of treatment
4 weeks
Part 2: Sustained Virological Response (SVR)
Tidsram: From drug administration until 12 weeks after end of treatment, up to 52 weeks
Part 2: Sustained virological response (SVR), defined as HCV RNA <25 IU/mL and undetectable at 12 weeks after end of treatment
From drug administration until 12 weeks after end of treatment, up to 52 weeks
Part 3 and 4: Sustained Virological Response (SVR)
Tidsram: From drug administration until 12 weeks after end of treatment, up to 36 weeks
Part 3 and 4: Sustained virological response (SVR) defined as HCV RNA <25IU/mL and undetectable at 12 weeks after end of treatment
From drug administration until 12 weeks after end of treatment, up to 36 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part 1: Time to Virological Response
Tidsram: From drug administration until end of drug administration, up to 4 weeks
Part 1: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
From drug administration until end of drug administration, up to 4 weeks
Part 2: Time to Virological Response
Tidsram: From drug administration until end of drug administration, up to 40 weeks
Part 2: Time to virological response, defined as the timepoint of the first measurement of plasma HCV RNA level <25 IU/mL. The percentage of participants who achieved virological response within each time period are displayed for this outcome measure.
From drug administration until end of drug administration, up to 40 weeks
Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4
Tidsram: 4 weeks
Part 1 and 2: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level not detectable at Week 4
4 weeks
Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment
Tidsram: 4 weeks and 24 weeks after the end of treatment, up to 64 weeks
Part 2: Sustained virological response at 4 and 24 weeks after end of treatment
4 weeks and 24 weeks after the end of treatment, up to 64 weeks
Part 3 and 4: Plasma HCV RNA Level <25 IU/mL at Week 4 and 12 of Treatment
Tidsram: Week 4 and 12
Part 3 and 4: Plasma Hepatitis C Virus Ribonucleic acid (HCV RNA) level <25 IU/mL at week 4 and 12 of treatment
Week 4 and 12
Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment
Tidsram: up to 28 weeks
Part 3 and 4: Sustained virological response (SVR) at 4 weeks after end of treatment
up to 28 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 maj 2010

Primärt slutförande (Faktisk)

1 oktober 2014

Avslutad studie (Faktisk)

1 oktober 2014

Studieregistreringsdatum

Först inskickad

3 maj 2010

Först inskickad som uppfyllde QC-kriterierna

26 maj 2010

Första postat (Uppskatta)

28 maj 2010

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

1 februari 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

22 december 2015

Senast verifierad

1 december 2015

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera